|
Terry Winters, Ph.D., Chairman and
CEO |
| |
Dr. Winters received his Ph.D. in organic chemistry from the
University of Wales. He is a founding general partner in Columbine
Venture Fund. Dr. Winters has specialized in creating medical
device and pharmaceutical companies based on university sourced
technology. He is currently a Special Limited Partner of Valley
Ventures and assists in funding and managing life science
investments. He is a board member of Amplimed, Afferon, AzERx and
Epitan. |
|
Kameron Maxwell, Ph.D., COO |
| |
Dr. Maxwell received his Ph.D. in Immunology from University of
Utah in Salt Lake City and has been involved with the clinical
development of drugs and for over 20 years . He previously held
positions at Genta Inc. and Baxter Travenol’s Hyland Division in
Costa Mesa, California. Dr. Maxwell was also founder and president
of Americal Pharmaceuticals Incorporated. At VTI, he is
responsible for all operations, including CMC and clinical
development. All employess report to Dr Maxwell. |
|
Jan P. Barker, Executive Vice President, Marketing and Business Development |
| |
Ms. Barker received a BS, from the University of San Francisco and an MS, from the University California, Davis/Stanford University. Ms. Barker brings wide-ranging experience to the Vital Therapies team. She has a broad combination of complementary skills in the healthcare entrepreneurial environment. Her diverse experience has included management, sales and marketing, research and development, human resources, information technology, development of e-healthcare technology and systems, devices and manufacturing. She is currently a Special Limited Partner with MedVenture Associates, a participant in the funding of Vital Therapies, and has worked/invested with private and public corporations in the healthcare systems, technology and medical device industries, including IPCM, The Hospitalist Company (S-1 Filed), PointShare, Networks for Healthcare, Alere Medical, Incorporated (Aquired), MedPartners, Inc., Lucile Salter Packard Children's Hospital at Stanford. |
Aron Stern, Vice President, CFO, Secretary and
Treasurer |
| |
Mr. Stern received a B.S. degree in
Economics and Business Administration and an M.B.A. in Finance and
Marketing from the University of California – Berkeley. Mr. Stern
has over 20 years of experience in capital formation,
acquisitions, financial strategy and financial and operational
management in growth-stage high technology and biotechnology
companies. He previously held positions at Apple Computer and Isis
Pharmaceuticals, and for 9 years was CFO at Protein Polymer
Technologies Inc., 4-D Neuroimaging, and for 3 years at VitaGen.
|
|
Dan Zhang, M.D., Executive Vice President of Vital Therapies Inc. and President of Vital Therapies (Beijing) Co. Ltd. |
|
Dr. Zhang received his pre-med training from Beijing University, his M.D. from Peking Union Medical College, an MPH from Harvard School of Public Health, and a master’s degree in healthcare management from Wharton Business School.
Dr. Zhang has more than ten years of drug/device development experience, including head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc. where he managed the Italian company’s North American clinical development programs, and as a vice president at Quintiles Transnational Corp. and member of its Executive Operating Committee, responsible for the Greater China Area.
Before joining Quintiles, Dr. Zhang has provided consulting services to many healthcare companies, including Eli Lilly, Pharmacia & Upjohn, Inc., Medtronic, Inc. and CIGNA Health Care, which included clinical trial design, health economic studies, pricing and market-entry strategies.
Dr. Zhang has established a strong working relationship with government and academic institutions in China, including the Ministry of Science and Technology and Shanghai Medical University. He is currently a senior consultant to the Chinese Academy of Medical Sciences/Peking Union Medical College, and President of the Chinese Biopharmaceutical Association-USA (CBA).
|
|
John Brotherton, Ph.D, Vice-President, Technology and
Product Development |
| |
Dr. Brotherton received his Ph.D. in Chemical Engineering from
the University of California, San Diego. His expertise includes
the design of hollow fiber bioreactors for support of mammalian
cell growth. Dr. Brotherton held positions including as an
engineer at the Space Systems Division of General Dynamics, and 7
years at VitaGen in the design, development and testing of the
ELAD® System, including the bedside unit. |
|
Dar He, M.D., Vice-President, International
Operations |
| |
Dr He is an M.D. from Shanghai First Medical University, P.R.
China, where he did clinical research in liver pathology. His
postdoctoral fellowship work at University of California Davis
involved cancer therapy, and at Baylor College of Medicine
Department of Pathology he studied liver disease and developing
clones from human primary hepatocytes. Dr. He joined Hepatix in
1990 and has been involved in research and development of
ELAD® for 7 years, and the manufacturing of
ELAD® for 6 years through all clinical testing. He is
an expert in nurturing and growing the cell line and preparing the
ELAD® cartridges. |
|
Shapour Aslani, Ph.D., Director, Quality Control and
Quality Assurance |
| |
Dr. Aslani received his Ph.D. in Chemistry from the University
of Houston. His prior experience includes quality control and
production management positions in companies both in the U.S. and
Iran. He held positions with VitaGen for 7 years, responsible for
manufacturing QC and maintaining cGMP
compliance. |
|
Marty Banas, Associate Director, Process Development |
| |
Mr. Banas received his degree in Biochemistry at the University of
Minnesota. As Director of Technical Services at Unisyn, Mr. Banas
has been involved with Hepatix/VitaGen for over 13 years and was
responsible for the installation and service of their production
systems. He joined Vital Therapies in December of 2005 bringing
over 20 years of experience in the engineering, service, and GMP
production of hollow fiber bioreactor production systems.
At VTI, he is responsible for the next generation of large-scale
production systems. |
